The estimated Net Worth of Ronald Kirk Huntsman is at least $263 millier dollars as of 20 June 2023. Ronald Huntsman owns over 14,000 units of Vivos Therapeutics stock worth over $263,024 and over the last 4 years Ronald sold VVOS stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ronald Huntsman VVOS stock SEC Form 4 insiders trading
Ronald has made over 10 trades of the Vivos Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Ronald bought 14,000 units of VVOS stock worth $7,420 on 20 June 2023.
The largest trade Ronald's ever made was buying 20,000 units of Vivos Therapeutics stock on 23 December 2022 worth over $10,000. On average, Ronald trades about 7,210 units every 77 days since 2020. As of 20 June 2023 Ronald still owns at least 86,521 units of Vivos Therapeutics stock.
You can see the complete history of Ronald Huntsman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Ronald Huntsman's mailing address?
Ronald's mailing address filed with the SEC is 7921 SOUTHPARK PLAZA,, SUITE 210, LITTLETON, CO, 80120.
Insiders trading at Vivos Therapeutics
Over the last 4 years, insiders at Vivos Therapeutics have traded over $0 worth of Vivos Therapeutics stock and bought 88,521 units worth $136,211 . The most active insiders traders include Anja B Krammer, Ronald Kirk Huntsman et Bradford K. Amman. On average, Vivos Therapeutics executives and independent directors trade stock every 77 days with the average trade being worth of $22,426. The most recent stock trade was executed by Ronald Kirk Huntsman on 20 June 2023, trading 14,000 units of VVOS stock currently worth $7,420.
What does Vivos Therapeutics do?
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
What does Vivos Therapeutics's logo look like?
Complete history of Ronald Huntsman stock trades at Vivos Therapeutics
Vivos Therapeutics executives and stock owners
Vivos Therapeutics executives and other stock owners filed with the SEC include:
-
R. Kirk Huntsman,
Co-Founder, Chairman & CEO -
Dr. Gurdev Dave Singh D.M.D., Ph.D.,
Founder, Chief Medical Officer & Director -
Bradford K. Amman,
CFO, Treasurer & Sec. -
Ruth Hembree,
Sr. VP -
Nicholas M. DeGennaro,
Sr. VP of the Medical Integration Division -
David Bryan Ferre,
Sr. VP of Marketing -
Cathryn H. Bonar,
Chief Compliance Officer and Sr. VP of Compliance & Medical Billing -
Edward A. Loew,
Chief Strategy Officer, Sr. VP of Strategy & Investor Relations Officer -
Susan McCullough,
Co-Founder & Sr. VP of Operations -
RaeAnn Byrnes,
Co-Founder and Sr. VP of People, Training & Devel. -
Todd Huntsman,
Co-Founder & Sr. VP of Manufacturing -
Bradford K. Amman,
Chief Financial Officer -
Leonard J Sokolow,
Director -
Anja B Krammer,
Director -
Ralph Elias Green,
Director -
Mark F. Lindsay,
Director -
Gurdev Dave Singh,
Chief Medical Officer -
Matthew Thompson,
Director -
Ronald Kirk Huntsman,
Chief Executive Officer